Literature DB >> 9024244

Thyrotropin receptor autoantibodies in serum are present at much lower levels than thyroid peroxidase autoantibodies: analysis by flow cytometry.

J C Jaume1, A Kakinuma, G D Chazenbalk, B Rapoport, S M McLachlan.   

Abstract

Using Chinese hamster ovary (CHO) cells that express high numbers of TSH receptor (TSHR) on their surface, we studied the feasibility of detecting directly by flow cytometry the binding of autoantibodies in patients' sera to the native TSHR. After using a serum (BBI) with high potency in the TSH binding inhibition (TBI) assay to establish the protocol, we studied an additional 38 sera: 10 without TBI activity (1-4.2% inhibition), 10 with moderately high TBI values (17.3-39.4% inhibition), 10 with high TBI levels (52-95.1% inhibition), 4 from normal individuals without autoimmune thyroid disease, and 4 from patients with systemic lupus erythematosus. We observed that a number of sera, including some without thyroid autoantibodies, contain antibodies against unknown antigens on CHO cells. Preadsorption with untransfected CHO cells before addition to the TSHR-10,000 cells eliminated or greatly reduced this nonspecific background. None of the sera from normal individuals, subjects with negative TBI values, or patients with systemic autoimmunity generated a positive signal on flow cytometry with TSHR-10,000 cells relative to the signal on untransfected cells. Remarkably, only 4 of 21 TBI-positive sera (including BBI) unequivocally recognized the TSHR on flow cytometry. In contrast, when thyroid peroxidase (TPO) autoantibodies in the same sera were studied using CHO cells overexpressing TPO on their surface, all 20 sera with TPO autoantibodies clearly elicited positive net fluorescence relative to untransfected cells. Study of the potent serum, BBI, revealed similar fluorescence (approximately 250 U) for TPO autoantibodies and TSHR autoantibodies at dilutions of 1:1000 and 1:10, respectively. Thus, by flow cytometry, the titer of TPO autoantibodies in the BBI serum is about 100-fold higher than that for TSHR autoantibodies in the same serum. In conclusion, the present data provide the strongest support for the idea that TSHR autoantibodies in the sera of patients with autoimmune thyroid disease are present at much lower levels than are TPO autoantibodies. This finding has important implications for the diagnostic detection of TSHR autoantibodies and for understanding the pathogenesis of Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024244     DOI: 10.1210/jcem.82.2.3740

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.

Authors:  X M Yan; J Guo; P Pichurin; K Tanaka; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  A monoclonal thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Alla Pritsker; Thomas Moran; Yuji Nagayama; Terry F Davies
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

3.  Limitations of the semisynthetic library approach for obtaining human monoclonal autoantibodies to the thyrotropin receptor of Graves' disease.

Authors:  J H Van Der Heijden; T W De Bruin; K A Glaudemans; J De Kruif; J P Banga; T Logtenberg
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

Review 4.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

5.  Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Chun-Rong Chen; Basil Rapoport
Journal:  Thyroid       Date:  2012-07-24       Impact factor: 6.568

6.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 7.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

8.  The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen.

Authors:  I Muller; L Zhang; C Giani; C M Dayan; M E Ludgate; F Grennan-Jones
Journal:  J Endocrinol Invest       Date:  2015-08-08       Impact factor: 4.256

9.  Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Terry F Davies
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

10.  Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves' disease.

Authors:  Yumiko Mizutori; Chun-Rong Chen; Francesco Latrofa; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Endocrinol Metab       Date:  2008-12-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.